Intro
After a pharmaceutical company introduced a new treatment for PsA into the market, they sought additional data on the drug’s effectiveness in real-world clinical practice. This company engaged OM1 to conduct a longitudinal, retrospective study using the OM1 PsA Registry, a syndicated dataset comprised of patient demographics and characteristics, treatment details, and clinician- and patient-reported outcomes.